David P. Hudesman, MD

Ellen J. Scherl, MD, comments on the limited role of mesalamine and steroids for moderate-to-severe ulcerative colitis treatment.

Marla Dubinsky, MD, emphasizes the role of shared decision-making and patient goals of therapy when approaching treatment selection for ulcerative colitis.

Drs David P. Hudesman, Marla Dubinsky, and Ellen J. Scherl explore the impact of IBD and ulcerative colitis on a patient’s quality of life.

Ellen J. Scherl, MD, highlights the different subtypes of ulcerative colitis and the differential diagnosis with Crohn’s disease.

David P. Hudesman, MD, and Marla Dubinsky, MD, define symptoms and potential disease triggers for inflammatory bowel disease (IBD).